← Back to Analyst Consensus 
TARS Buy
Tarsus Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 8, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Aug 12, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Jul 31, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jul 21, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 4, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 25, 2026 | Oppenheimer | maintain | Outperform → Outperform | $105 | 52% |
| Feb 25, 2026 | Guggenheim | maintain | Buy → Buy | $90 | 52% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $100 | 53% |
| Nov 20, 2025 | Mizuho | initiate | — → Outperform | $100 | 52% |
| Nov 5, 2025 | Guggenheim | maintain | Buy → Buy | $87 | 52% |
| Oct 20, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $88 | 44% |
| May 5, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $51 | 54% |
| May 2, 2025 | Guggenheim | maintain | Buy → Buy | $84 | 52% |
| Mar 6, 2025 | Jefferies | maintain | Buy → Buy | $58 | 52% |
| Feb 26, 2025 | Guggenheim | maintain | Buy → Buy | $78 | 52% |
| Feb 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $73 | 44% |
| Feb 26, 2025 | Barclays | maintain | Overweight → Overweight | $60 | 53% |
| Feb 24, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Feb 10, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Jan 27, 2025 | Barclays | maintain | Overweight → Overweight | $62 | 53% |
| Jan 22, 2025 | Oppenheimer | maintain | Outperform → Outperform | $72 | 52% |
| Nov 15, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $41 | 54% |
| Nov 14, 2024 | Oppenheimer | maintain | Outperform → Outperform | $65 | 52% |
| Aug 9, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $63 | 52% |
| May 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $61 | 44% |
| May 10, 2024 | Barclays | maintain | Overweight → Overweight | $60 | 53% |
| May 9, 2024 | Oppenheimer | maintain | Outperform → Outperform | $61 | 52% |
| Mar 6, 2024 | Jefferies | maintain | Buy → Buy | $44 | 52% |
| Feb 29, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $30 | 54% |
| Feb 28, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $57 | 44% |
| Feb 28, 2024 | Barclays | maintain | Overweight → Overweight | $50 | 53% |
| Feb 28, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $59 | 52% |
| Nov 20, 2023 | Goldman Sachs | initiate | — → Neutral | $19 | 54% |
| Nov 10, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Sep 11, 2023 | Guggenheim | maintain | Buy → Buy | $49 | 52% |
| Aug 14, 2023 | Guggenheim | reiterate | Buy → Buy | $46 | 52% |
| Aug 11, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $42 | 44% |
| Jul 26, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Jul 18, 2023 | William Blair | initiate | — → Outperform | $44 | 48% |
| Jun 26, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $44 | 44% |
| Jun 16, 2023 | Guggenheim | maintain | — → Buy | $42 | 52% |
| May 18, 2023 | Guggenheim | initiate | — → Buy | $0 | 52% |
| May 8, 2023 | Oppenheimer | reiterate | — → Outperform | $43 | 52% |
| Mar 15, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $40 | 44% |
| Aug 1, 2022 | Barclays | initiate | — → Overweight | $40 | 53% |
| Dec 21, 2021 | HC Wainwright & Co. | initiate | — → Buy | $40 | 44% |
| Nov 23, 2021 | Oppenheimer | initiate | — → Outperform | $55 | 52% |
| Oct 8, 2021 | Raymond James | maintain | — → Strong Buy | $65 | 54% |
| Jun 29, 2021 | Raymond James | maintain | — → Strong Buy | $50 | 54% |
Price Target Trend
Jun 3, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days